Posoleucel Medicine 07 December 2022 Extended indication Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Posoleucel Domain Infectious diseases Reason of inclusion New medicine (specialité) Main indication Viral infections other Extended indication Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant. Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer AlloVir Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity Unknown ATMP Yes Submission date 2023 Expected Registration 2024 Orphan drug Yes Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Estimated primary completion datum fase 3 studie in augustus 2022. Therapeutic value Current treatment options letermovir Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation beperkte meerwaarde verwacht Duration of treatment Frequency of administration Dosage per administration 2-4 milliliter. References NCT04693637 Additional remarks Expected patient volume per year Patient volume 5 - 10 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Expert opinie(1); Additional remarks Jaarlijks worden in Nederland circa 600 allogene stamceltransplantaties uitgevoerd. Echter, gezien de beperkte meerwaarde zal slechts een klein deel hiervan in aanmerking komen. Er wordt verwacht dat er ongeveer 5 tot 10 patiënten per jaar behandeld zullen worden (1). Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Yes Indication extensions Mogelijk in de toekomst ingezet bij niertransplantaties References Additional remarks Other information Additional remarks